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Background and objective: Telemonitoring (TM) of patients with COPD has gained much 
interest, but studies have produced conflicting results. We aimed to investigate the effect of TM 
with the option of video consultations on quality of life (QoL) in patients with severe COPD.
Patients and methods: COPD patients at high risk of exacerbations were eligible for the 
6-month study and a total of 281 patients were equally randomized to either TM (n=141) or 
usual care (n=140). TM comprised recording of symptoms, oxygen saturation, spirometry, and 
video consultations. Algorithms generated alerts if readings breached thresholds. Both groups 
filled in a health-related QoL questionnaire (15D©) and the COPD Assessment Test (CAT) at 
baseline and at 6 months. Within-group differences were analyzed by paired t-test.
Results: Most of the enrolled patients had severe COPD (86% with Global Initiative for Chronic 
Obstructive Lung Disease stage 3 or 4 and 45% with admission for COPD within the last year, 
respectively). No difference in drop-out rate and mortality was found between the groups, 
and likewise there was no difference in 15D or CAT at baseline. At 6 months, a significant 
improvement of 0.016 in 15D score (p=0.03; minimal clinically important difference 0.015) 
was observed in the TM group (compared to baseline), while there was no improvement in 
the control group -0.003 (p=0.68). After stratifying 15D score at baseline to ,0.75 or $0.75, 
respectively, there was a significant difference in the ,0.75 TM group of 0.037 (p=0.001), which 
is a substantial improvement. No statistically significant changes were found in CAT score.
Conclusion: Compared to the nonintervention group, TM as an add-on to usual care over a 
6-month period improved QoL, as assessed by the 15D questionnaire, in patients with severe 
COPD, whereas no difference between groups was observed in CAT score.
Keywords: COPD, tele–health care, video consultations, quality of life
Introduction
Trailing in the wake of decline of lung function in COPD patients, diminishing 
physical, emotional, and social functioning leads to a deterioration in quality of life 
(QoL).1 Furthermore, a substantial prevalence of psychological distress further adds 
to the considerable adverse effects on QoL.2,3
Telemonitoring (TM) may have the potential to alleviate some of the burdens that 
COPD places on patients QoL, not only by providing rapid medical intervention in 
the early phase of deterioration in the patient’s condition, and by that prevent hospital 
admissions, but also a way of reducing costs and time spent in transportation.4
To date, TM has been assessed in several different designs and setups, but results are 
conflicting, though mostly negative. Review articles published to date have struggled 
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in extracting significant conclusions and, as it goes, have 
recommended additional and more extensive studies.5–7
Three large studies have examined TM as an alternative to 
either home or outpatient clinic visits, with differing results. 
Pinnock et al8 and Trappenburg et al9 published their find-
ings from 2 large randomized studies with COPD patients 
and reported that TM had no significant effects on QoL. 
McDowell’s et al10 reported from a large 2-center randomized 
trial that TM has a positive impact on health-related QoL and 
anxiety. As TM involves substantial healthcare costs and 
commitment, there is a need for well-designed longer-term 
studies with appropriate follow-up to determine whether it 
is suitable for widespread application.7,11,12 Further studies 
are, therefore, clearly needed in order to establish whether 
or not TM has clinically relevant impact on QoL in patients 
with COPD.
The present randomized study aimed to investigate the 
impact of TM with the option of video consultations on QoL 
in patients with severe and very severe COPD recruited from 
respiratory outpatient clinics.
Patients and methods
eligible patients
The NetKOL study was a randomized controlled trial 
recruited patients from 4 hospitals with specialized pulmo-
nary wards in Copenhagen (Hvidovre, Bispebjerg, Herlev, 
and Amager Hospitals).
The target population were patients with severe and very 
severe, stable COPD at high risk of exacerbations and hospital 
admissions. The inclusion criteria were as follows:
1. A diagnosis of COPD defined according to the Global 
Initiative for Chronic Obstructive Lung Disease criteria13 
(post-bronchodilator forced expiratory volume in 
1 second [FEV
1
]/forced vital capacity ,0.7).
2. Post-bronchodilator FEV
1
,60% of predicted (pred) 
value.
3. Hospital admission due to COPD exacerbation within the 
previous 36 months and/or prescribed long-term oxygen 
therapy (LTOT) due to chronic respiratory failure for at 
least 3 months.
4. Regularly scheduled visits to the respiratory outpatient 
clinics.
5. COPD judged by the study staff as the leading cause of 
disability.
6. Residents in 1 of 6 municipalities in the Copenhagen area 
and the catchment area of 1 of the 4 recruiting hospitals.
The exclusion criteria were as follows:
1. An exacerbation of COPD within the 3 weeks before 
enrollment.
2. Unwilling to provide informed consent for participating 
in the study.
3. Unable to use a tablet computer.
4. Planned stay outside the catchment area for 2 weeks or 
more during the study period.
5. Inability to participate due to language barrier or cognitive 
disorders.
6. Impossible to setup a functioning telephone line.
In case of hospital admission, patients continued in the 
study immediately after discharge from the hospital.
Patient recruitment and randomization
Over a 6-month inclusion period, we identified 560 eligible 
patients, of whom 281 (51.2%) patients gave written 
informed consent to study participation and were random-
ized to either TM or usual care (control group) with a 1:1 
allocation for 6 months. Randomized patients were divided 
into 3 categories:
Group 1 – Hospital admission for COPD in the previous 
year.
Group 2 – Hospital admission for COPD in the past 
3 years, but not within the year before enrollment.
Group 3 – LTOT regardless of the number of hospitalisa-
tions for COPD in previous years.
Block randomization was used to ensure equal numbers 
of patients from the 3 groups were allocated to TM and 
usual care.
standard management of COPD
All trial patients were managed and treated according to 
national and international guidelines. Usual care included 
outpatient pulmonary rehabilitation for patients with 
FEV
1
,50% predicted and Medical Research Council dysp-
nea score $314 and supported discharge to selected in-hospital 
patients to reduce the risk of early readmission.15
Usual care group
Patients were seen for scheduled visits at the outpatient 
clinics once or twice a year and for unscheduled visits as 
required. In case of acute respiratory problems, patients could 
contact the staff at the outpatient clinic Monday to Friday, 
during the daytime. Depending on their mobility, patients on 
LTOT were seen either at the outpatient clinics or at home 
by a respiratory care nurse.
TM group (intervention group)
Patients randomized to the TM group were not seen at 
regularly scheduled visits at the outpatient clinics during the 
6-month study period, but unscheduled visits were arranged 
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if the TM consultation was considered inadequate by the 
health care professional.
The TM equipment comprised a tablet computer with 
a web camera, a microphone, and measurement equipment 
(spirometer, pulse oximeter, and bathroom scale). Patients 
reported changes in dyspnea, sputum color, volume, and 
purulence on the tablet computer. Measurements, including 
lung function, oxygen saturation, and body weight, and video 
consultations, together with the other measurements, were 
conducted at regular intervals, ie, once a week for the first 
4 weeks of the study period and then every 4 weeks.16 Consul-
tations without video, but with the other measurements, were 
performed every week throughout the study period. Patients 
were free to carry out additional measurements at any time 
or phone the call center during open hours. The observa-
tions were transferred to the call center at each participant’s 
local hospital and automatically categorized and prioritized 
(ie, coded green, yellow, or red), and aberrant measurements 
were responded to by the specialist nurse either by phone or 
video consultation and if relevant conferred with a respiratory 
specialist. All measurements were stored in a secured data-
base; access was granted to the patient’s general practitioner 
and the municipal’s social and health workers.
A more detailed description of the design of the present 
study is given in Ringbaek et al.16
Measurements of outcome variables
To measure the QoL, we selected 2 questionnaires, the 15D© 
and the COPD assessment test (CAT). The 15D questionnaire 
is a standardized 15-dimensional self-administered generic 
questionnaire. It assesses mobility, vision, hearing, breathing, 
sleeping, eating, speech, excretion, activities (usual), mental 
function, discomfort and symptoms, depression, distress, vital-
ity, and sexual activity. There are 5 levels of each area of assess-
ment (scored 1–5), and the resulting score is between 0 and 1. 
One is equal to perfect health and well-being; a score of 0 is 
equal to a state of death.17 The 15D questionnaire has previously 
been found to be comparable to the AQ20 score as a generic 
measure of health-related QoL.18 The CAT, a disease-specific 
health status questionnaire, provides a measure of disease 
severity from the patient’s perspective. It contains 8 questions 
(cough, phlegm, chest tightness, breathlessness, activities, 
confidence, sleep, and energy) that pertain to a patient’s 
COPD symptom burden. Each question consist of a 6-point 
differential scale, and the final score is between 0 and 40.19
Outcomes and ethics
The primary outcome was the change in health-related QoL 
as measured by the 15D questionnaire, with change in CAT 
score as the secondary efficacy parameter. Patients completed 
both questionnaires at baseline and again at 6-months (end 
of study period).
The study was approved by the Research Ethics Com-
mittee of the Capital Region of Denmark (H-4-2013-052).
statistics
Data were analyzed with the statistical package SPSS 
version 24.0 (IBM Corporation, Armonk, NY, USA). The 
Fisher’s exact test, unpaired t-test, and Mann–Whitney U test 
were used, as appropriate, for comparisons between groups 
at baseline. For analyses of changes in 15D and CAT scores 
(including standard deviation), within-group differences 
were calculated using paired t-test. For between-group dif-
ferences at follow-up, we calculated the values using analysis 
of covariance to account for baseline 15D and CAT scores. 
The 0.75 cut-point for 15D was based on the rounded median 
of the groups. A 2-sided p-value of ,0.05 was considered 
significant.
Results
Baseline characteristics
A total of 207 COPD patients (85.7%) enrolled in the study 
had an FEV
1
,50% pred, 148 patients (52.7%) had a Medical 
Resrach Council dyspnea score $4, and 126 patients (44.9%) 
had at least 1 hospital admission for COPD in the year 
before enrollment (Table 1). More females were allocated 
to TM; further comparisons between the 2 groups are given 
in Table 1.
study completion and withdrawals
Four patients (3 in the TM group) withdrew their consent 
within the first 2 weeks of the study period, and 2 patients 
dropped out due to technical issues. Seventeen patients died 
during the study period, and 10 patients dropped out for other 
reasons (technical issues after the first 2 weeks or did not have 
the energy to carry on anymore). No significant differences 
in drop-out rates (p=0.79) or mortality were found between 
the groups (p=0.87).
15D Qol questionnaire
In total, 140 patients in the TM group and 139 patients in the 
usual care group completed baseline CAT and the 15D ques-
tionnaire with no significant differences in scores between 
the 2 groups (Table 2). Of the enrolled patients, 123 from the 
TM group and 123 from the usual care group completed the 
follow-up assessment questionnaires at 6 months. We found 
a statistically significant (p=0.03) within-group difference 
of 0.0162 by paired t-test in the TM group’s change from 
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baseline (Table 2). We found a statistically significant dif-
ference between groups at follow-up; the TM group had a 
higher mean 15D score of 0.0222 (95% CI: 0.0023–0.0421, 
p=0.03) compared with the usual care group. There was a 
numerical, but statistically nonsignificant difference in CAT 
score at follow-up, and the TM group had a mean score 
of -0.59 (95% CI: -1.86 to 0.67, p=0.36) lower than the 
usual care group.
After stratifying subjects by 15D score at baseline using 
a cut-off of 0.75, we found a statistically significant within-
group difference in 15D in the TM group having a baseline 
score below 0.75 of 0.037 (p=0.001). The 0.75 cut-point was 
chosen based on it being the rounded median for the groups. 
There was no significant change in 15D scores for the above 
0.75 TM group or both control groups.
CaT
There was no significant difference in CAT score between 
groups at baseline, though the TM group had a 1.6 point 
lower mean CAT score than the control group. There was 
no significant within-group change between baseline and 
follow-up in paired t-test. Both groups had a similar change 
in CAT score between baseline and follow-up (Table 3).
Discussion
The present randomized clinical trial revealed that TM 
with close contact between the patient and the health care 
providers at the hospital had a positive impact on QoL in 
patients with more severe COPD. To date, there have been 
multiple studies looking at the usefulness and potential appli-
cation of TM. Results from these studies show that TM is not 
Table 1 Baseline characteristics of the 281 patients enrolled in the study and randomized to either TM (n=141) or usual care (n=140)
Characteristics TM group (N=141) Usual care group (N=140) P-value
Females, n (%) 86 (61%) 64 (45%) 0.01a
age in years, mean (sD) 69.8 (9.0) 69.4 (10.1) 0.75b
BMI, kg/m2, mean (sD) 24.9 (6.3) 26.9 (7.0) 0.01b
FeV1 % predicted, mean (sD) 34.9 (13.3) 33.8 (12.0) 0.48
b
MrC dyspnea score, mean (sD) 3.5 (0.8) 3.7 (0.9) 0.09c
Pack-years, mean (sD) 42.9 (26.4) 41.0 (22.7) 0.72b
lTOT, n (%) 37 (26%) 38 (27%) 0.86a
Charlson comorbidity index, mean (sD) 1.70 (1.49) 1.96 (1.51) 0.13
living alone 58% 52% 0.27c
number of hospital admissions for COPD 
exacerbation last year, mean (range)
0.91 (0–7) 1.22 (0–23) 0.61a
Note: aMann–Whitney U test. bUnpaired t-test. cFisher’s exact test.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; lTOT, long-term oxygen therapy; MrC, Medical research Council; TM, telemonitoring.
Table 2 Qol, as assessed by the 15D© score, at baseline, follow-up, as change within-group from baseline for the TM and usual care 
groups and difference at follow-up between TM and usual care
 TM group (N=141) Usual care group (N=140)
15D baseline, mean (sD) 0.735a (0.101) 0.726a (0.113)
15D 6-month follow-up, mean (sD) 0.761b (0.107) 0.728c (0.121)
Within-group difference, mean 0.016b (0.002–0.031)d
p=0.03e
-0.003c (-0.018 to 0.012)d
p=0.68e
Between-group difference at follow-up, mean 0.0222 (0.0049–0.0622)d
p=0.02f
TM + usual care groups stratified by 
baseline 15D score
,0.75 (N=62) $0.75 (N=60) ,0.75 (N=71) $0.75 (N=52)
15D baseline, mean (sD) 0.666 (0.065) 0.824 (0.057) 0.656 (0.076) 0.834 (0.054)
15D 6-months follow-up, mean (sD) 0.703 (sD =0.095) 0.819 (sD =0.083) 0.661 (sD =0.100) 0.819 (sD =0.082)
15D change to 6-month follow-up, mean 0.037
(0.016–0.059)d
p=0.001e
-0.005
(-0.024 to 0.013)d
p=0.569e
0.006
(-0.015 to 0.026)d
p=0.588e
-0.015
(-0.037 to 0.007)d
p=0.186e
Notes: aNonsignificant difference. bOnly 122 patients completed follow-up 15D. cOnly 123 patients completed follow-up 15D. d95% confidence interval of the difference. 
ePaired t-test. fanalysis of covariance.
Abbreviations: Qol, quality of life; TM, telemonitoring.
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a clear-cut and straightforward solution that will improve 
all COPD patients’ QoL, prevent exacerbations, and reduce 
hospitals costs. However, there are evident inclinations that 
TM will have a valuable place in specific, selected circum-
stances. The question is who can TM be beneficial to and in 
which areas can we expect TM to be successful? Based on our 
findings we will discuss the potential place for TM to improve 
QoL in selected severe and very severe COPD patients.
Changes in Qol
COPD patients in the TM group had a significant, but a small 
improvement in the QoL.
The minimum important change (MIC) in the 15D ques-
tionnaire has previously been evaluated by Alanne et al.20 
They found the MIC of 15D to be ±0.015 and anchored 
the results to a 5-level subjective global assessment scale 
(1: much better, 2: slightly better, 3: much the same, 
4: slightly worse, and 5: much worse) (Figure 1). The change 
seen in 15D score in the TM group equates, only just, to a 
global assessment score of 2 or slightly better. However, 
we find a group with potential for substantial improvement 
when selecting patients with a lower than median (,0.75) 
QoL score as measured by the 15D questionnaire. The TM 
patients with a lower than median 15D score at baseline had a 
change equivalent to a global assessment score of 1, or much 
better, at follow-up. The between-group difference equates to 
a clinically significant difference. However, there is at present 
no available study that has examined whether the MIC found 
by Alanne et al20 applies to between-group differences, but 
the assumption is that for now the same MIC applies.
Both McDowell et al10 with Saint George Respiratory 
Questionnaire (SGRQ) and Hospital Anxiety and Depression 
Scale (HADS) and Koff et al21 with, SGRQ found similar 
improvements in QoL, with a similar TM setup, where 
monitoring and follow-up are maintained by the same respi-
ratory nurses. Pinnock et al8 found an improvement in QoL, 
but with no difference between treatment arms, ie, TM and 
control group. In this setup, information was only monitored 
by the study group, and in case of aberrant findings, they were 
relayed to the patient’s general practitioner and action was at 
the GP’s discretion. In our study and that of McDowell et al,10 
monitoring was performed and followed up by the designated 
respiratory nurses in each center, in cooperation with a respi-
ratory physician. Trappenburg et al9 used the clinical COPD 
questionnaire to determine the change in health-related QoL 
and found no significant effect of TM. The clinical COPD 
questionnaire score is based on the degree of symptoms and 
physical functioning, but not on aspects such as mood that 
is registered by the 15D, HADS, and SGRQ questionnaires. 
As we have found based on our patients’ CAT score, TM 
has no significant effect on symptoms and functioning but 
improves when accounting for mood and outlook. We specu-
late that the reason we find a significant improvement, 
lies in the setup of the TM (that is very different between 
studies) with regular face-to-face or telephone interaction 
and follow-up action taken by the same team.
Changes in CaT score
We found no significant difference in CAT score between 
the TM and the usual care group at follow-up, and showed 
a similar nonsignificant decrease between baseline and 
6-month follow-up. However, this is likely due to dropouts 
from the trial were patients with the highest baseline CAT 
score (median 30 for dropouts’ vs 27 for completion to 
follow-up). Seeing as our intervention was merely monitoring 
and not for a new medicine or a new type of rehabilitation, 
it is not expected to improve symptom burden.
Figure 1 Clinically significant changes in the 15D© Qol score anchored to a global 
assessment scale of 1–5, by standardized algorithm transformed into an index 
from 0 to 1.
Abbreviation: Qol, quality of life.
???? ?????? ????????????????????????????????
?? ???????????????????
?? ????????????????????????????????
?? ????????????????????????????
?? ????????????????????????????????
?? ???????????????????
Table 3 Qol, as assessed by the CaT score, at baseline, follow-
up and as change within-group from baseline for the TM and usual 
care groups
 TM group  
(N=141)
Usual care  
group (N=140)
CaT baseline,  
mean (sD)
26.9a (6.7) 28.5a (7.9)
CaT 6-month  
follow-up, mean (sD)
25.6b (6.9) 27.5c (7.5)
Within-group  
difference, mean
-0.76
(-1.68 to 0.15)d
p=0.101e
-0.73
(-1.74 to 0.28)d
p=0.154e
Between-group  
difference, mean
-0.59
(-1.86 to 0.67)d
p=0.36f
Notes: aNonsignificant difference. bOnly 122 patients completed follow-up CaT. 
cOnly 123 patients completed follow-up CaT. d95% confidence interval of the 
difference. ePaired t-test. fanalysis of covariance.
Abbreviations: CaT, COPD assessment Test; TM, telemonitoring; Qol, quality 
of life.
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Conclusion
Our findings suggest that TM has a potential role in improv-
ing the QoL of COPD patients overall, despite not improving 
symptoms and exacerbations, and not least in patients with 
a lower than median score of QoL. We found that patients 
who were randomized to TM in addition to usual care showed 
a clinically and statistically significant improvement in the 
QoL. Future studies should aim at determining the optimal 
cut-off point for 15D or other health-related QoL assessments 
for selecting TM candidates.
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